PI3K/AKT/mTOR通路
文献计量学
工程伦理学
政治学
计算机科学
数据科学
钥匙(锁)
生物医学
工程类
管理科学
作者
Lu Liang,Meijuan Wang,Zhaoyang Liu,Shuchao Wang
出处
期刊:Cns & Neurological Disorders-drug Targets
[Bentham Science Publishers]
日期:2026-01-07
卷期号:25
标识
DOI:10.2174/0118715273398806251024072412
摘要
INTRODUCTION: Neuroinflammation is a key pathological process in neurological disorders, from acute injuries to chronic diseases such as Alzheimer's Disease (AD), Parkinson's Disease (PD), and stroke. The mTOR pathway regulates neuroinflammation by influencing microglial activation, autophagy, and synaptic plasticity. To address the scarcity of systematic analyses in this growing field, our study employs bibliometric analysis to map the landscape, identify key themes and collaborations, and highlight therapeutic targets for future neurological research. METHODS: A Web of Science search retrieved articles published up to 2024. Bibliometric analysis and visualization were conducted using VOSviewer, CiteSpace, Charticulator, and Microsoft Excel. RESULTS: A total of 509 articles were examined, showing a fluctuating increase in publications and citations. China had the highest output, and the Journal of Neuroinflammation was the most active journal. Mehan Sidharth emerged as a leading researcher. The most cited study was "HIF1α- dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells". Findings revealed strong links between neuroinflammation and AD, PD, and stroke, and highlighted mTOR inhibitors as promising therapeutic agents. DISCUSSION: Our analysis identified highly-cited works, current trends, emerging frontiers, and the significance of mTOR inhibitors. However, the comprehensiveness of our bibliometric approach may have been limited by the field's vast scope and by analytical disparities between CiteSpace and VOSviewer, potentially resulting in omissions. CONCLUSION: This study provides an overview of scientific progress on mTOR signaling and neuroinflammation, emphasizing its key role in disease mechanisms and suggesting directions for therapeutic innovation.
科研通智能强力驱动
Strongly Powered by AbleSci AI